Document Detail

The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol.
MedLine Citation:
PMID:  15321024     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: This study evaluated systemic and ocular acute safety and intraocular pressure (IOP)-lowering efficacy of travoprost 0.004% and bimatoprost 0.03%, compared to brimonidine 0.2% and betaxolol 0.25% in healthy subjects. PATIENTS AND METHOD: Nineteen (19) young men, ages between 24 and 42, were enrolled in a single-center, institutional randomized, double-masked, crossover clinical trial. Baseline IOP, heart rate, blood pressure, and respiratory rate were recorded at hour 0. At minute 30, heart rate, blood pressure, respiratory rate, and spirometry were measured. At hour 1, color Doppler imaging of retrobulbar vessels was performed. At hour 2, heart rate, blood pressure, and respiratory rate were measured; spirometry and a 15-minute treadmill test were performed. The same protocol was applied after one drop of a study medication was instilled into each eye on four subsequent visits at 5-day intervals. RESULTS: Travoprost and bimatoprost did not cause significant reductions in systolic blood pressure during exercise and recovery. The mean respiratory rate and forced expiratory volume in 1 second were not significantly altered by any study medication. Travoprost reduced the resistive index and increased blood velocities in the ophthalmic artery and its branches. Bimatoprost caused a significant increase in end diastolic velocity of the ophthalmic artery. At hour 6, all medications reduced IOP significantly (p < 0.05). The most frequent ocular side effect of travoprost and bimatoprost was conjunctival hyperemia. CONCLUSION: Travoprost and bimatoprost were found to be systemically safe and caused an increase in blood-flow velocities of the retrobulbar vessels after a single-dose application. Their ocular hypotensive effect was comparable to that of brimonidine and greater than that of betaxolol in healthy subjects.
Umit Ubeyt Inan; Sitki Samet Ermis; Ayse Orman; Ersel Onrat; Aylin Yucel; Faruk Ozturk; Ali Asagidag; Atac Celik
Related Documents :
11464074 - Interaction between delta-9-tetrahydrocannabinol and indomethacin.
19668444 - Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intra...
19874254 - Bimatoprost - a review.
9932994 - Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in gl...
588514 - Outflow changes in positive provocative tests.
2814574 - Stroke mortality in miyagi, japan.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics     Volume:  20     ISSN:  1080-7683     ISO Abbreviation:  J Ocul Pharmacol Ther     Publication Date:  2004 Aug 
Date Detail:
Created Date:  2004-08-23     Completed Date:  2005-02-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9511091     Medline TA:  J Ocul Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  293-310     Citation Subset:  IM    
Kocatepe University School of Medicine, Department of Ophthalmology, Afyon, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Betaxolol / administration & dosage*,  toxicity
Cardiovascular System / drug effects*
Cloprostenol / administration & dosage*,  analogs & derivatives*,  toxicity
Cross-Over Studies
Double-Blind Method
Eye / blood supply,  drug effects
Intraocular Pressure / drug effects*,  physiology
Lipids / administration & dosage*,  toxicity
Ocular Hypotension / chemically induced
Prospective Studies
Pulmonary Circulation / drug effects,  physiology
Quinoxalines / administration & dosage*,  toxicity
Regional Blood Flow / drug effects,  physiology
Reg. No./Substance:
0/Amides; 0/Lipids; 0/Quinoxalines; 0/bimatoprost; 157283-68-6/travoprost; 40665-92-7/Cloprostenol; 59803-98-4/brimonidine; 63659-18-7/Betaxolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rab...
Next Document:  Effects of dihydrogenation of flavones and number of hydroxy groups in the molecules on ocular blood...